Rolls ends 'thrilling' rights issue after vaccine boost
Rolls-Royce, the UK aerospace company, completed its rights issue on Thursday, with the cash call proving to be a resounding success. The deal benefited from a late boost on Monday, when US drug company Pfizer said it had enjoyed successful late-stage trials for a Covid-19 vaccine, giving investors hope that Rolls-Royce engines would be powering more planes into the sky sooner than expected.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts